SHUTTLEWORTH, STEPHEN JOSEPH,CECIL, ALEXANDER RICHARD LIAM,SILVA, FRANCK ALEXANDRE
申请号：
SG11201606576U
公开号：
SG11201606576UA
申请日:
2015.02.12
申请国别(地区):
SG
年份:
2016
代理人:
摘要：
or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S； each X is independently CH or N； R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O； R2 is LY； each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene； Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O； and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110δ, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.
